Noroozbeygi Amin, Dehkordi Mahboubeh Adami, Masoomi Mahya, Salarifar Elnaz
Mashhad Azad University of Medical Sciences, Mashhad, Iran.
Mashhad Azad University of Medical Sciences, Mashahd, Iran.
Indian J Otolaryngol Head Neck Surg. 2024 Feb;76(1):794-803. doi: 10.1007/s12070-023-04282-3. Epub 2023 Nov 13.
Although the Epley maneuver is considered the primary treatment in BPPV, anti-vertigo medications are effective in residual symptoms. This study was designed to compare betahistine and dimenhydrinate plus the Epley maneuver and the Epley maneuver alone. This prospective cohort study was performed in Mashhad, Iran, from 2013 to 2015. 90 adult patients diagnosed with BPPV in hospitals and ENT clinics were selected through convenience sampling. Patients received betahistine 8 mg TDS or dimenhydrinate 50 mg once daily plus Epley or the Epley alone for four weeks. SF-36 and the DHI were used before and after the treatment. 49 were females (54.4%). The mean (SD) age was 47.9 (8.7) years. There was no significant difference between the groups in age ( = 0.753) and gender ( = 0.050).There were significant differences in all areas of SF-36 except for social activities in the dimenhydrinate group. There was a marginally significant difference between the betahistine and dimenhydrinate groups in role limitation due to physical health problems ( = 0.046). There were significant differences between the females and males in emotional well-being before and after treatment in the dimenhydrinate group ( = 0.014) and in terms of role limitation due to physical health problems in the Epley maneuver group ( = 0.022). Older patients in the betahistine group had better social activities after treatment ( = 0.048). In severe forms of BPPV, betahistine or dimenhydrinate might effectively reduce the symptoms.
尽管Epley手法被认为是良性阵发性位置性眩晕(BPPV)的主要治疗方法,但抗眩晕药物对残留症状有效。本研究旨在比较倍他司汀和茶苯海明加Epley手法与单纯Epley手法的疗效。这项前瞻性队列研究于2013年至2015年在伊朗马什哈德进行。通过方便抽样从医院和耳鼻喉科诊所选取了90例被诊断为BPPV的成年患者。患者接受8毫克倍他司汀每日三次或50毫克茶苯海明每日一次加Epley手法或单纯Epley手法治疗四周。在治疗前后使用SF - 36健康调查简表和眩晕残疾评定量表(DHI)。49例为女性(54.4%)。平均(标准差)年龄为47.9(8.7)岁。两组在年龄(P = 0.753)和性别(P = 0.050)方面无显著差异。除茶苯海明组的社会活动外,SF - 36的所有领域均存在显著差异。倍他司汀组和茶苯海明组在因身体健康问题导致的角色限制方面存在边缘显著差异(P = 0.046)。茶苯海明组治疗前后女性和男性在情感健康方面存在显著差异(P = 0.014),Epley手法组在因身体健康问题导致的角色限制方面存在显著差异(P = 0.022)。倍他司汀组年龄较大的患者治疗后社会活动情况较好(P = 0.048)。在严重形式的BPPV中,倍他司汀或茶苯海明可能有效减轻症状。